Maintenance treatment with the TLR9 agonist lefitolimod in extensive-stage small-cell lung cancer (ES-SCLC): Final results from the randomized phase II IMPULSE study

被引：0
|
作者：
Thomas, M. [1 ]
Ponce Aix, S. [2 ]
Navarro Mendivil, A. [3 ]
Riera Knorrenschild, J. [4 ]
Schmidt, M. [5 ]
Wiegert, E. [6 ]
Kapp, K. [7 ]
Mauri, C. [8 ]
Domine Gomez, M. [9 ]
Kollmeier, J. [10 ]
Sadjadian, P. [11 ]
Froehling, K-P. [12 ]
Huber, R. M. [13 ]
Wolf, M. [14 ]
机构：
[1] Heidelberg Univ Hosp, Thorac Oncol, German Ctr Lung Res DZL, Translat Lung Res Ctr Heidelberg TLRC H,Thoraxkli, Heidelberg, Germany
[2] Univ Hosp 12 Octubre, Med Oncol, Madrid, Spain
[3] Vall dHebron Univ Hosp, Vall dHebron Inst Res VHIR, Barcelona, Spain
[4] Uniklinikum Giessen & Marburg, Klin Hamatol Onkol & Immunol, Marburg, Germany
[5] Mologen AG, Early & Translat R&D, Berlin, Germany
[6] Mologen AG, Clin Dev, Berlin, Germany
[7] Mologen AG, Translat R&D, Berlin, Germany
[8] UCL, Div Med, London, England
[9] Fdn Jimenez Diaz, Dept Med Oncol, Univ Hosp, Madrid, Spain
[10] Helios Klinikum Emil von Behring GmbH, Lungenklin Heckeshorn, Berlin, Germany
[11] Johannes Weseling Klinikum, Klin Hamatol Onkol & Palliat Med, Minden, Germany
[12] Kath Klinikum Koblenz Montabaur, Klin Innere Med Pneumol, Koblenz, Germany
[13] Univ Munich, LMU Klinikum, Thorac Oncol Ctr Munich, Munich, Germany
[14] Klin Kassel, Med Klin 4, Kassel, Germany
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1672P
引用
收藏
页码：599 / 599
页数：1
相关论文
共 50 条
  • [41] A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study protocol
    Tetsuhiko Asao
    Satoshi Watanabe
    Takahiro Tanaka
    Satoshi Morita
    Kunihiko Kobayashi
    BMC Cancer, 22
  • [42] Extensive stage small cell lung cancer (ES-SCLC) and palliative care disparities: a national cancer database study
    Khullar, Karishma
    Plascak, Jesse J.
    Habib, Muhammad Hamza
    Nagengast, Samantha
    Parikh, Rahul R.
    BMJ SUPPORTIVE & PALLIATIVE CARE, 2024, 14 (E3) : E2694 - E2699
  • [43] Financial toxicity of front-line platinum etoposide plus atezolizumab versus durvalumab in extensive-stage small-cell (ES-SCLC) lung cancer.
    Harrison, Bradley
    Keith, Nicole
    Verbyla, Allison
    Mileham, Kathryn Finch
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (28) : 23 - 23
  • [44] Anlotinib as Maintenance Therapy for Extensive-stage Small-cell Lung Cancer: A Single-arm, Prospective, Phase II Study
    Kong, F.
    Wang, Z.
    Wang, N.
    Zhang, D.
    Liao, D.
    Zhang, J.
    Su, C.
    Jia, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S691 - S692
  • [45] A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study protocol
    Asao, Tetsuhiko
    Watanabe, Satoshi
    Tanaka, Takahiro
    Morita, Satoshi
    Kobayashi, Kunihiko
    BMC CANCER, 2022, 22 (01)
  • [46] Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study
    Kong, Tiandong
    Chen, Lu
    Zhao, Xiaoli
    Duan, Fangfang
    Zhou, Hanli
    Wang, Lei
    Liu, Danna
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (05) : 1095 - 1105
  • [47] REAL-WORLD TREATMENT PATTERNS, HEALTHCARE RESOURCE UTILIZATION (HCRU) AND CLINICAL OUTCOMES OF PATIENTS WITH EXTENSIVE-STAGE SMALL-CELL LUNG CANCER (ES-SCLC) IN ALBERTA, CANADA
    Suri, G.
    Boyne, D. J.
    Caveen, M.
    Mak, D.
    Takundwa, R.
    Wani, R. J.
    Cheung, W.
    VALUE IN HEALTH, 2024, 27 (06) : S23 - S23
  • [48] Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study
    Tiandong Kong
    Lu Chen
    Xiaoli Zhao
    Fangfang Duan
    Hanli Zhou
    Lei Wang
    Danna Liu
    Investigational New Drugs, 2022, 40 : 1095 - 1105
  • [49] Toripalimab and anlotinib as a maintenance treatment for extensive-stage small-cell lung cancer: a case report
    Wu, Guixian
    Huang, Jing
    Lin, Ling
    Yan, Shuangquan
    Pan, Weijia
    Chen, Qian
    Wu, Xiaomai
    Lv, Dongqing
    IMMUNOTHERAPY, 2022, 14 (13) : 1007 - 1013
  • [50] Epirubicin/paclitaxel/etoposide in extensive-stage small-cell lung cancer: a phase I–II study
    C Tibaldi
    T Prochilo
    F Russo
    M C Pennucci
    A Del Freo
    F Innocenti
    A Fabbri
    A Falcone
    P F Conte
    E Baldini
    British Journal of Cancer, 2006, 94 : 1263 - 1266
12345